Client success story
Target Discovery Platform Design & Implementation
Business Value: Increased Productivity and Target Validation Enablement Leads to Funding
Summary: Designing a Collaborative Drug Target Review Platform
bPrescient designed and built a platform for reviewing and prioritizing drug targets from a large set of computational data, allowing our client to prioritize and validate their highest-value targets. This led to reduced frustration for the scientists and to higher quality science and increased productivity overall.
Challenge: Manual Processes and Large Data Sets Delay Target Prioritization
This oncology therapeutics company had built a sophisticated computational pipeline that had successfully identified thousands of potential drug targets using novel bioinformatics approaches. Reviewing and prioritizing these targets was a manual and time-consuming process and the data was kept in spreadsheets which were difficult to share and annotate consistently. The company needed a way for their team to collaborate on reviewing and prioritizing targets so they could make the right decisions about where to direct their efforts.
Solution: bPrescient Experts Build Integrated Target Discovery Platform
bPrescient designed and developed an integrated platform for reviewing, assessing, and prioritizing candidate targets. The first phase of the project involved defining requirements and the user interface for the platform, which included defining capabilities for ingesting target data from various sources, incorporating analysis tools, enabling querying and filtering capabilities, and integrating proteomics and immunopeptidomics data. Following the design phase, bPrescient implemented the platform in an iterative manner, building the most important features first and reviewing priorities continuously.
Outcome: High-Quality Targets Accelerate Therapeutic Development
The resulting platform allowed the company’s scientists to review, analyze, and annotate large amounts of data on potential drug targets, resulting in high quality, prioritized lists of targets that could be validated in the lab. These validated targets formed the basis for their next phase of funding and therapeutic development.
Let’s talk
Tell us about your toughest R&D challenge and let’s discuss how bPrescient can solve it.
